学术海报


Clinical Trial Program Management: Dos & Don'ts
作者:  来源:  发布时间:2018年12月16日 14:43  浏览次数:

主讲人:Linda (Ruimei) Li

时间:20181217 9:30

地点:科研楼五层报告厅

报告题目:Clinical Trial Program Management: Dos & Don'ts

主讲人简介:

Linda (Ruimei) Li, M.D., Ph.D., GCP, CCRA CEO of GCP Clinica Service.

Dr. Li obtained M.D. in Epidemiology and M.Sc. in Public Health from Shandong Medical University, Ph.D. in Pathology from National University of Singapore, completed postdoctoral fellowship at NIH, USA.

Dr. Li is a seasoned medical professional with 20+ years of experience and increasing responsibility and leadership roles at investigator site (MD Anderson Cancer Center), CRO industry (ICON PLC), large pharmaceutical company(Gilead), and small biotech companies(NANTKWEST, ASTEX Pharma, etc.), US government (NIH) and CDC subsidiary in China. Thorough knowledge and understanding of FDA and EMEA, PMDA, and CFDA Regulations, ICH Guidelines, and GCPs/GVPs governing the conduct of clinical trials. Lead over 40 global clinical trials with focuses on oncology, virology and inflammation. Contributed to 10 new drug/vaccine approvals in USA, EU, China, and NDA filing of Epclusa for HCV in Japan, etc. Developed global clinical programs in combination therapy of multiple investigational products from proof of concept to late stage development. Supervised all levels of clinical study teams. Proven capability to evaluate and translate complex scientific/clinical data, identify safety and efficacy signals, prepare and review all regulatory and clinical documents. Built up and maintained active connections with over 600 principal investigators (oncologists, rheumatologist and nephrologists) in North America and Asia, and over 300 HIV principal investigators globally.

    欢迎老师和同学们参加!

 
上一条:共生菌天然产物研究进展
下一条:核酸化员工物学—寡聚核苷酸的的精准修饰和功能调控

关闭

版权所有:网投领导者 地址:济南市文化西路44号 电话:0531-88382018 E-mail:pharma@sdu.edu.cn
 导航
网站导航

  学术海报

Clinical Trial Program Management: Dos & Don'ts
发布日期:2018-12-16  浏览次数:

主讲人:Linda (Ruimei) Li

时间:20181217 9:30

地点:科研楼五层报告厅

报告题目:Clinical Trial Program Management: Dos & Don'ts

主讲人简介:

Linda (Ruimei) Li, M.D., Ph.D., GCP, CCRA CEO of GCP Clinica Service.

Dr. Li obtained M.D. in Epidemiology and M.Sc. in Public Health from Shandong Medical University, Ph.D. in Pathology from National University of Singapore, completed postdoctoral fellowship at NIH, USA.

Dr. Li is a seasoned medical professional with 20+ years of experience and increasing responsibility and leadership roles at investigator site (MD Anderson Cancer Center), CRO industry (ICON PLC), large pharmaceutical company(Gilead), and small biotech companies(NANTKWEST, ASTEX Pharma, etc.), US government (NIH) and CDC subsidiary in China. Thorough knowledge and understanding of FDA and EMEA, PMDA, and CFDA Regulations, ICH Guidelines, and GCPs/GVPs governing the conduct of clinical trials. Lead over 40 global clinical trials with focuses on oncology, virology and inflammation. Contributed to 10 new drug/vaccine approvals in USA, EU, China, and NDA filing of Epclusa for HCV in Japan, etc. Developed global clinical programs in combination therapy of multiple investigational products from proof of concept to late stage development. Supervised all levels of clinical study teams. Proven capability to evaluate and translate complex scientific/clinical data, identify safety and efficacy signals, prepare and review all regulatory and clinical documents. Built up and maintained active connections with over 600 principal investigators (oncologists, rheumatologist and nephrologists) in North America and Asia, and over 300 HIV principal investigators globally.

    欢迎老师和同学们参加!

 
上一条:共生菌天然产物研究进展
下一条:核酸化员工物学—寡聚核苷酸的的精准修饰和功能调控

关闭


版权所有:网投领导者